Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 2/20 | 0.52 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 15/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 14/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 12/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907607 | 0.87 | UGCG (0.48) | UGCGMRGPRX1ADRA1AADRA1BADRA1D | |
| SCHEMBL24464302 | 0.82 | ADRA1A (0.42) | UGCGADRA1AADRA1BADRA1DKDM4E | |
| SCHEMBL24464357 | 0.82 | UGCG (0.60) | UGCGMRGPRX1 | |
| SCHEMBL29907618 | 0.82 | UGCG (0.62) | UGCGMRGPRX1 | |
| SCHEMBL29907403 | 0.81 | UGCG (0.60) | UGCGMRGPRX1 | |
| SCHEMBL24464284 | 0.81 | UGCG (0.60) | UGCGMRGPRX1 | |
| SCHEMBL24464346 | 0.80 | UGCG (0.53) | UGCGMRGPRX1 | |
| SCHEMBL24464277 | 0.80 | UGCG (0.53) | UGCGMRGPRX1 | |
| SCHEMBL29907613 | 0.80 | UGCG (0.83) | UGCGMRGPRX1 | |
| SCHEMBL29907685 | 0.80 | UGCG (0.69) | UGCGMRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885MRGPRX1 2038/4885ADRA1A 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.